Seoul Pharma Co. Ltd (018680) - Total Liabilities

Latest as of September 2025: ₩32.70 Billion KRW ≈ $22.16 Million USD

Based on the latest financial reports, Seoul Pharma Co. Ltd (018680) has total liabilities worth ₩32.70 Billion KRW (≈ $22.16 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 018680 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Seoul Pharma Co. Ltd - Total Liabilities Trend (2012–2024)

This chart illustrates how Seoul Pharma Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Seoul Pharma Co. Ltd (018680) total assets.

Seoul Pharma Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Seoul Pharma Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Domo Activos Socimi SA MC:DOMO	Spain	€215.90K
JPMorgan Japanese Investment Trust LSE:JFJ	UK	GBX69.60 Million
Sapura Industrial Bhd KLSE:7811	Malaysia	RM96.11 Million
DT&C Co. Ltd KQ:187220	Korea	₩153.17 Billion
Macompta Fr Sa PA:MLMCA	France	€1.38 Million
Geratherm Medical AG XETRA:GME	Germany	€6.95 Million
Volution Group plc LSE:FAN	UK	GBX332.47 Million
Deltamac Taiwan Co Ltd TWO:6144	Taiwan	NT$53.16 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Seoul Pharma Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Seoul Pharma Co. Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.17	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.79	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.44	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Seoul Pharma Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Seoul Pharma Co. Ltd (2012–2024)

The table below shows the annual total liabilities of Seoul Pharma Co. Ltd from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩31.45 Billion ≈ $21.31 Million	+27.11%
2023-12-31	₩24.74 Billion ≈ $16.77 Million	-8.39%
2022-12-31	₩27.01 Billion ≈ $18.30 Million	-37.62%
2021-12-31	₩43.29 Billion ≈ $29.34 Million	+19.48%
2020-12-31	₩36.23 Billion ≈ $24.56 Million	-14.62%
2019-12-31	₩42.44 Billion ≈ $28.76 Million	+5.43%
2018-12-31	₩40.25 Billion ≈ $27.28 Million	+21.70%
2017-12-31	₩33.08 Billion ≈ $22.42 Million	-34.47%
2016-12-31	₩50.47 Billion ≈ $34.20 Million	+2.70%
2015-12-31	₩49.15 Billion ≈ $33.31 Million	+2.65%
2014-12-31	₩47.88 Billion ≈ $32.45 Million	+22.23%
2013-12-31	₩39.17 Billion ≈ $26.55 Million	+10.99%
2012-12-31	₩35.29 Billion ≈ $23.92 Million	--

About Seoul Pharma Co. Ltd

KQ:018680 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$15.52 Million

₩22.90 Billion KRW

Market Cap Rank

#25988 Global

#1949 in Korea

Share Price

₩1964.00

Change (1 day)

-0.51%

52-Week Range

₩1932.00 - ₩3230.00

All Time High

₩17976.69